4569 杏林製薬

累計 / 通期：4Q / 3Q / 2Q / 1Q

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2026/03	4Q	126,257	3,567	2.8%	4,031	3.2%	3,448	2.7%	60.03	-2.9%	-71.6%	-69.5%	-62.1%
2025/03	4Q	130,087	12,567	9.7%	13,219	10.2%	9,086	7.0%	158.17	8.8%	109.0%	100.2%	70.7%
2024/03	4Q	119,532	6,013	5.0%	6,602	5.5%	5,322	4.5%	92.74	5.5%	17.4%	13.3%	12.7%
2023/03	4Q	113,270	5,123	4.5%	5,827	5.1%	4,723	4.2%	82.44	7.3%	2.3%	4.6%	20.1%
2022/03	4Q	105,534	5,007	4.7%	5,569	5.3%	3,932	3.7%	68.62	2.6%	-13.5%	-13.6%	-35.9%
2021/03	4Q	102,904	5,786	5.6%	6,447	6.3%	6,130	6.0%	106.99	-6.4%	-22.9%	-21.1%	-0.3%
2020/03	4Q	109,983	7,503	6.8%	8,175	7.4%	6,149	5.6%	107.35	-3.2%	-16.4%	-13.4%	-10.5%
2019/03	4Q	113,620	8,972	7.9%	9,438	8.3%	6,869	6.0%	104.68	-	-	-	-

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2026/03	4Q	126,257	3,567	2.8%	4,031	3.2%	3,448	2.7%	60.03	-2.9%	-71.6%	-69.5%	-62.1%
2025/03	4Q	130,087	12,567	9.7%	13,219	10.2%	9,086	7.0%	158.17	8.8%	109.0%	100.2%	70.7%
2024/03	4Q	119,532	6,013	5.0%	6,602	5.5%	5,322	4.5%	92.74	5.5%	17.4%	13.3%	12.7%
2023/03	4Q	113,270	5,123	4.5%	5,827	5.1%	4,723	4.2%	82.44	7.3%	2.3%	4.6%	20.1%
2022/03	4Q	105,534	5,007	4.7%	5,569	5.3%	3,932	3.7%	68.62	2.6%	-13.5%	-13.6%	-35.9%
2021/03	4Q	102,904	5,786	5.6%	6,447	6.3%	6,130	6.0%	106.99	-6.4%	-22.9%	-21.1%	-0.3%
2020/03	4Q	109,983	7,503	6.8%	8,175	7.4%	6,149	5.6%	107.35	-3.2%	-16.4%	-13.4%	-10.5%
2019/03	4Q	113,620	8,972	7.9%	9,438	8.3%	6,869	6.0%	104.68	-	-	-	-